LSNE gets European foothold with deal for sterile drug facility

LSNE lyophilization vials
CDMO Lyophilization Services of New England has added a European facility with the buyout of a sterile drug site in Spain. (LSNE)

Lyophilization Services of New England (LSNE) already has four facilities in the U.S., but it has now jumped the Atlantic to pick up its first location in Europe.

The Bedford, New Hampshire-based CDMO has completed a deal for a sterile drug manufacturing facility in Leon, Spain, it announced Monday. Terms of the deal were not disclosed by LSNE but in am email a spokeswoman said the plant with 87 employees was acquired from AMRI. 

“Acquiring this high quality facility in León was the logical next step in our growth strategy given our strong and growing client base in Europe,” said Matthew Halvorsen, CEO at lyophilization specialist LSNE.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Private equity fund buys out sterile injectables maker LSNE 

The CDMO, which is owned by private equity firm Permira, has three facilities in New Hampshire and one in Wisconsin.

The company said that the facility recently completed an FDA inspection as well as one by authorities in Spain so can serve both the U.S. and European markets.

The facility includes four high-speed aseptic fill lines and commercial-scale lyophilization so can handle both clinical and commercial products, according to LSNE. The acquisition also adds prefilled syringe, ophthalmic and sterile bulk lyophilization capabilities to the company.

LSNE said it intends for the new facility “to focus on pharmaceutical products that have complex requirements such as emulsions, suspensions, liposomal formulations and nanoparticle products.”

This is the second deal for LSNE since Permira bought it in 2017. Last year, it picked up from PSC Biotech a 37,000-square-foot aseptic fill-finish manufacturing facility in Madison, Wisconsin, that produces clinical supply.

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.